The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...
NEW YORK – Carsgen Therapeutics on Monday said it plans to seek approval in China for its autologous CAR T-cell therapy satricabtagene autoleucel (satri-cel) in previously treated patients with ...
BMSs Opdivo gains FDA approval for faster subcutaneous cancer treatment BMS secures FDA nod for rapid cancer treatment ...
Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Solid Tumor.
Ipilimumab + nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Dedifferentiated Liposarcoma.
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...
Becomes the first subcutaneously administered PD-1 inhibitor.
The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for ...
Opdivo Qvantig (nivolumab and hyaluronidase) has been approved for use across almost all of Opdivo's lengthy list of ...
US FDA approves Opdivo Qvantig injection, for subcutaneous use in most previously approved adult, solid tumour Opdivo indications: Princeton, New Jersey Monday, December 30, 2024, ...
Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor approved by the FDA. It is expected to be available in ...
The US Food and Drug Administration (FDA) on Friday approved nivolumab and hyaluronidase-nvhy, under the trade name Opdivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback